1. Home
  2. PRG vs CSTL Comparison

PRG vs CSTL Comparison

Compare PRG & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$28.14

Market Cap

1.3B

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$25.60

Market Cap

806.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRG
CSTL
Founded
2020
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
806.3M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
PRG
CSTL
Price
$28.14
$25.60
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$47.50
$47.17
AVG Volume (30 Days)
563.7K
387.5K
Earning Date
04-22-2026
05-04-2026
Dividend Yield
1.79%
N/A
EPS Growth
N/A
N/A
EPS
3.59
N/A
Revenue
$2,409,223,000.00
$344,229,000.00
Revenue This Year
$25.27
$2.10
Revenue Next Year
$6.59
$12.63
P/E Ratio
$7.84
N/A
Revenue Growth
N/A
3.66
52 Week Low
$23.50
$14.59
52 Week High
$41.14
$44.28

Technical Indicators

Market Signals
Indicator
PRG
CSTL
Relative Strength Index (RSI) 32.25 28.37
Support Level $27.39 $21.77
Resistance Level $30.68 $34.97
Average True Range (ATR) 1.33 1.23
MACD -0.71 0.08
Stochastic Oscillator 2.07 12.13

Price Performance

Historical Comparison
PRG
CSTL

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Share on Social Networks: